Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)

The University of Texas System (UT)

Status and phase

Completed

Phase 2

Conditions

Metastatic Castrate-resistant Prostate Cancer

mCRPC

Treatments

Drug: Sipuleucel-T

Radiation: Stereotactic Ablative Body Radiation

Study type

Interventional

Funder types

Other

Identifiers

NCT01818986

STU 102012-026

Details and patient eligibility

About

In this i-SABR (immunotherapy + Stereotactic Ablative Body Radiation) trial, the stereotactic radiation to multiple metastatic sites is delivered not only to eradicate sites of bulky progressive disease, but also to provide antigen presentation and immune stimulation which is expected to act synergistically to the concurrently administered immunotherapy Sipuleucel-T and thereby significantly improve the treatment outcome for metastatic castrate resistant prostate cancer patients (mCRPC). Both Sipuleucel-T and SABR are FDA approved therapeutic cancer treatment

Enrollment

20 patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Biopsy proven prostate cancer
Patient must currently be on androgen deprivation or anti-androgen therapy with castrate levels of testosterone (< 50ng/dl). Medical castration should continue until disease progression
Radiographic evidence of metastatic disease documented with bone scan or CT scan. Patients with any number of metastatic site are allowed to enroll. However, only up to six sites will be selected for SBRT treatment, at the discretion of the treating radiation oncologist.
PSA ≥ 5 ng/ml
Asymptomatic or minimally symptomatic patients1. Visual Analog Scale (VAS) ≤ 4;vNo narcotic use in the last 21 days
Adequate hematologic, renal, and liver function
Previous treatment with surgery, radiation or hormonal therapy is allowed.
Performance status ECOG 0 or 1.
Life expectancy of at least 6 months
Negative serology tests for human immunodeficiency virus (HIV) 1 and 2, human T cell lymphotropic virus (HTLV)-1, Hepatitis B and C.
Age ≥ 18 years.
Ability to understand and the willingness to sign a written informed consent

Exclusion criteria

Subjects must not have had more than two different regiments of chemotherapy previously or any chemotherapy within the past three months.
Subjects may not be receiving any other investigational agents for the treatment of prostate cancer.
Subjects with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
Subjects with malignant pleural effusions and malignant ascites
Systemic corticosteroid use within past 28 days. Use of inhaled, intranasal, and topical steroids is acceptable.
Systemic immunosuppressive therapy in the past 28 days.
Use of any of the following within the past 28 days: Megestrol acetate (Megace®), diethyl stilbestrol (DES), or cyproterone acetate, Ketoconazole, high dose calcitriol [1,25(OH)2VitD] (i.e., > 7.0 μg/week).
Inability to tolerate contrast dye for baseline CT imaging.
Initiation or discontinuation of biphosphonate use within past 28 days.
Subjects with pathologic long-bone fractures
Subjects with spinal cord compression
Paget's disease of bone.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.